NEW YORK, Oct. 31, 2014 /PRNewswire/ -- OTC Markets
Group Inc. (OTCQX: OTCM), operator of Open, Transparent and
Connected financial marketplaces, today announced ANGLE plc (AIM:
AGL; OTCQX: ANPCY), a specialist medical diagnostics company, has
qualified to have its American Depositary Receipts (ADRs) trade on
OTCQX®, the best marketplace.
Logo -
http://photos.prnewswire.com/prnh/20110118/MM31963LOGO
ANGLE begins trading today on OTCQX under the symbol "ANPCY,"
where each ADR represents 10 ordinary shares. U.S. investors can
find current financial disclosure and Real-Time Level 2 quotes for
the company on www.otcmarkets.com.
"We are pleased to welcome ANGLE to the OTCQX marketplace," said
R. Cromwell Coulson, President and
CEO of OTC Markets Group. "ANGLE joins the growing number of
global companies that are choosing to trade on OTCQX to provide
U.S. investors transparent trading and convenient access to their
news and financials so they can more easily analyze, value and
trade their securities. We look forward to supporting ANGLE as
the company expands its presence in the U.S.
market."
ANGLE's Founder and Chief Executive, Andrew Newland, commented, "We believe that the
steps that we are taking will substantially strengthen ANGLE's
position in the United States, the
world's largest market for medical diagnostics. The ADR
program on the OTCQX marketplace will meet U.S. investor demand and
increase liquidity in ANGLE's shares to the benefit of our
shareholders."
Aegis Capital Corp. serves as ANGLE's Principal American Liaison
("PAL") on OTCQX, responsible for providing professional guidance
on OTCQX requirements.
ANGLE is a commercially driven specialist medical diagnostic
company with pioneering products in cancer diagnostics and fetal
health.
ANGLE's lead product is the Parsortix cell separation system,
which can capture very rare cells from blood. This includes
circulating tumor cells (CTCs) in cancer patient blood even when
there is less than one CTC in one billion healthy cells. The
resulting liquid biopsy (simple blood test) enables the
investigation of mutations in the patient's cancer for personalized
cancer care.
ANGLE has launched a product for the research market and has
secured CE Mark regulatory approval for the clinical market in
Europe. The FDA authorization is
in process.
About OTC Markets Group Inc.
OTC Markets Group Inc.
(OTCQX: OTCM) operates Open, Transparent and Connected financial
marketplaces for 10,000 U.S. and global securities. Through
our OTC Link® ATS, we directly link a diverse network of
broker-dealers that provide liquidity and execution services for a
wide spectrum of securities. We organize these securities into
marketplaces to better inform investors of opportunities and risks
– OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace;
and OTC Pink®, The Open Marketplace. Our data-driven platform
enables investors to easily trade through the broker of their
choice at the best possible price and empowers a broad range of
companies to improve the quality and availability of information
for their investors. To learn more about how we create better
informed and more efficient financial marketplaces, visit
www.otcmarkets.com.
OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
Subscribe to the OTC Markets RSS Feed
SOURCE OTC Markets Group Inc.
